RET signaling pathway and RET inhibitors in human cancer
Rearranged during transfection (RET) receptor tyrosine kinase was first identified over thirty years ago as a novel transforming gene. Since its discovery and subsequent pathway characterization, RET alterations have been identified in numerous cancer types and are most prevalent in thyroid carcinom...
Main Authors: | Angelina T. Regua, Mariana Najjar, Hui-Wen Lo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.932353/full |
Similar Items
-
Precision oncology for RET-related tumors
by: Antonella Verrienti, et al.
Published: (2022-08-01) -
Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
by: Rui Wan, et al.
Published: (2024-01-01) -
A comprehensive overview of the relationship between RET gene and tumor occurrence
by: Lu Zhao, et al.
Published: (2023-02-01) -
RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy
by: Tomasz Kucharczyk, et al.
Published: (2022-10-01) -
RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma (PTC)
by: Cristina eRomei, et al.
Published: (2012-04-01)